Navigation Links
Explaining chemotherapy-associated nausea
Date:1/30/2008

PHILADELPHIA (January 29, 2008) -- A new study from the Monell Center increases understanding of the biological mechanisms responsible for the nausea and vomiting that often afflict patients undergoing chemotherapy. The findings could lead to the development of new approaches to combat these debilitating side effects.

By increasing knowledge of what causes the nausea and vomiting that accompany chemotherapy treatment, we move closer to providing patients with less traumatic and hopefully more effective drug treatment regimens, said lead author Bart De Jonghe, PhD, a Monell physiologist.

Anorexia (loss of appetite) and cachexia (a syndrome of physical wasting and weight loss) often accompany chemotherapy-induced symptoms of nausea and vomiting. These side effects can compromise the patients nutritional status and impede recovery.

The research, published online in the American Journal of Physiology, uses a rat model to identify a nerve that transmits signals of chemotherapy-associated illness from the small intestine to the brain.

To explore whether sensory nerves traveling from the intestinal system to the brain contribute to nausea and illness associated with chemotherapy, the Monell researchers examined the incidence of pica in rats that received the potent chemotherapy drug cisplatin. Cisplatin treatment, widely used for a variety of cancers, is highly associated with nausea and vomiting.

Pica is the term used to describe the eating of non-food substances, such as clay or dirt. Because rats which do not vomit eat clay when made sick by toxins, researchers measure pica behavior as an indicator of nausea and malaise in these animals.

In the Monell study, rats given cisplatin began to eat clay, decreased their food intake, and lost body weight.

The researchers found that cisplatin-associated pica was reduced by 60 percent when they cut a nerve that transmits sensory signals from the small intestine to the brain. Cutting the same nerve, known as the common hepatic branch of the vagus nerve, also lessened the reduction of food intake and loss of body weight.

These results suggest that the upper intestine is an important site for generation of the nausea and appetite loss associated with chemotherapy drugs.

The findings also help to define the neural systems involved in nausea and malaise, which can significantly impact the nutritional status of patients receiving potent drug treatments for diseases such as cancer or AIDS.

This nerve may be part of a natural detection system that we use to detect toxins in food, and it is possible that we are activating it with these strong medications, comments senior author Charles Horn, PhD, a behavioral neuroscientist at Monell.

Increased understanding of this system will enable development of specific blockers to reduce nausea and improve quality of life during chemotherapy and related therapeutic regimens.

Future studies also will evaluate whether the vagus nerve contributes to other side effects associated with chemotherapy, such as altered taste perception, fatigue, and stress.


'/>"/>

Contact: Leslie Stein
stein@monell.org
267-519-4707
Monell Chemical Senses Center
Source:Eurekalert

Related medicine news :

1. ADA Calls for Scientifically Accurate Patient Brochure Explaining Filling Choices
2. Mayo Clinic study finds FDA warning against antinausea drug droperidol unnecessary
3. Acupuncture does not reduce radiotherapy-induced nausea, but patients believe it does
4. No Link Between Anti-Nausea Drug, Heart Trouble
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
Breaking Medicine Technology: